US equities |
MU $1,074.89 ▲+0.00% INTC $119.13 ▼-0.17% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% SPCX $158.96 ▲+0.00% SNDK $1,719.99 ▲+0.00%
FinancialContent

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Commercially Launches Precise MRD with Select Community Oncologists
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 4 5 6 Next >